Erythropoietin Market in Japan 2015-2019

日本のエリスロポエチン市場

◆タイトル:Erythropoietin Market in Japan 2015-2019
◆商品コード:IRTNTR7268
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年9月9日
◆ページ数:65
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、日本のエリスロポエチン市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、日本のエリスロポエチン市場規模及び予測、用途別分析、製品別分析、需要先別分析、市場シェア、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About erythropoietin
Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein that is responsible for the production of erythrocytes in the body. In the fetal stage, this protein is produced in the liver. However, in adulthood it is produced in the kidneys. During anemic conditions, the body produces an excess of erythropoietin to maintain a normal level of red blood cells. When the endogenous production of erythropoietin is disrupted because of illness or medications, normal red blood cell levels are maintained by an injecting erythropoiesis-stimulating agents (ESAs). These agents are similar to natural erythropoietin in structure and function. They can be produced by recombinant DNA technology and are used in the treatment of anemia resulting from renal disease, cancer, HIV, injuries, or neurological conditions.

Technavio’s analysts forecast the erythropoietin market in Japan to decline at a CAGR of (1.16) % over the period 2014-2019.

[Covered in this report]
In this report, Technavio covers the present scenario and growth prospects of the erythropoietin market in Japan for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of erythropoietin drugs and biosimilars used in the treatment of anemia due to renal disease, chemotherapy, antiretroviral therapy, wounds, or neurological conditions.

Technavio’s report, Erythropoietin Market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the erythropoietin market in Japan and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.

[Key vendors]
• Chugai Pharmaceutical
• JCR Pharmaceuticals
• Kissei Pharmaceutical
• Kyowa Hakko Kirin

[Other prominent vendors]
• Eisai
• Otsuka
• Taiho Pharmaceutical
• Takeda

[Market driver]
• Increased incidence of anemia due to illness
• For a full, detailed list, view our report

[Market challenge]
• High cost of therapy
• For a full, detailed list, view our report

[Market trend]
• Strategic alliances
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Biosimilars and biologics industry
Overview
Emerging role of biosimilars
Factors influencing biosimilars and biologics industry
Biosimilars: Business and pricing strategy
Biosimilars industry: Viewpoints of providers, payers, buyers, vendors, and regulatory bodies

PART 06: Japan: Country snapshot
Pharmaceutical industry in Japan
Biosimilars and biologics industry in Japan
Regulatory landscape
Healthcare reforms
Erythropoietin: Addressable market in Japan

PART 07: Global erythropoietin drugs market

PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 09: Market segmentation by application
End-stage renal disease
Cancer
HIV
Wounds and neural disease

PART 10: Market segmentation by product
First-generation erythropoietin formulation
Second-generation erythropoietin formulation
Biosimilars

PART 11: Market segmentation by end-user
Hospitals
Pharmacies

PART 12: Market drivers
Increased incidence of anemia
Reimbursement for erythropoietin preparations
Favorable growth opportunities

PART 13: Impact of drivers

PART 14: Market challenges
Complex manufacturing process
Complicated regulatory framework
Physician’s reluctance to prescribe biosimilars

PART 15: Impact of drivers and challenges

PART 16: Market trends
Strategic alliances
Increased R&D of innovative molecule drugs
Focus on biosimilars

PART 17: Vendor landscape
Competitive scenario
Market share analysis 2014

PART 18: Key vendor analysis
Chugai Pharmaceutical
JCR Pharmaceuticals
Kissei Pharmaceutical
Kyowa Hakko Kirin

PART 19: Appendix
List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Definition of biosimilars by organizations
Exhibit 03: Factors influencing biosimilars and biologics industry
Exhibit 04: Patent expiries of branded biologics
Exhibit 05: Impact of biosimilar cost savings on various sectors
Exhibit 06: Factors affecting success of biosimilars
Exhibit 07: Biosimilars industry: Point-of-view
Exhibit 08: Revenue of pharmaceuticals in Japan 2013 and 2020 ($ billions)
Exhibit 09: Pharmaceutical R&D expenditure in Japan 2000-2012 ($ millions)
Exhibit 10: Japan’s percentage share in world imports of pharmaceuticals 2013
Exhibit 11: Japan’s percentage share in world exports of pharmaceutical 2013
Exhibit 12: Biosimilars approved by PMDA in Japan
Exhibit 13: Review process of biosimilars in Japan
Exhibit 14: Number of people with cancer in Japan 2010-2013
Exhibit 15: Incidence of cancers in Japan 2011
Exhibit 16: Approved erythropoietin biosimilars
Exhibit 17: Erythropoietin drugs market in Japan 2014-2019 ($ millions)
Exhibit 18: Five forces analysis
Exhibit 19: Erythropoietin drugs market in Japan by end-user 2014
Exhibit 20: Erythropoietin drugs market in Japan by product in hospitals 2014
Exhibit 21: Erythropoietin drugs market segmentation in Japan by product in retail pharmacies 2014
Exhibit 22: Number of people receiving dialysis in Japan 2008-2012
Exhibit 23: Impact of drivers
Exhibit 24: Impact of drivers and challenges
Exhibit 25: Kyowa Hakko Kirin: YoY growth and revenue of NESP 2010-2014 ($ millions)
Exhibit 26: Kyowa Hakko Kirin: YoY growth and revenue of ESPO/NESP 2010-2012 ($ millions)
Exhibit 27: Chugai Pharmaceutical: YoY growth and revenue of Epogin 2010-2014 ($ millions)
Exhibit 28: Chugai Pharmaceutical: YoY growth and revenue of Mircera 2011-2014 ($ millions)
Exhibit 29: JCR Pharmaceuticals: YoY growth and revenue of Epoietin alfa BS injection JCR 2011-2014 ($ millions)
Exhibit 30: Kissei Pharmaceuticals: YoY growth and revenue of Epoietin alfa BS injection (JCR) 2011-2014 ($ millions)
Exhibit 31: Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
Exhibit 32: Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 33: Kissei Pharmaceutical: Business segmentation by revenue 2015
Exhibit 34: Kissei Pharmaceutical: Business segmentation by revenue 2014 and 2015 ($ millions)
Exhibit 35: Kissei Pharmaceutical: Geographical segmentation by revenue 2015
Exhibit 36: Kyowa Hakko Kirin: Business segmentation by revenue 2014
Exhibit 37: Kyowa Hakko Kirin: Business segmentation by revenue 2013 and 2014
Exhibit 38: Kyowa Hakko Kirin: Geographical segmentation by revenue 2014



【掲載企業】

Chugai Pharmaceutical, JCR Pharmaceuticals, Kissei Pharmaceutical, Kyowa Hakko Kirin

【資料のキーワード】

エリスロポエチン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[日本のエリスロポエチン市場] (Erythropoietin Market in Japan 2015-2019 / IRTNTR7268)販売に関する免責事項
[日本のエリスロポエチン市場] (Erythropoietin Market in Japan 2015-2019 / IRTNTR7268)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆